San Diego-based Viking Therapeutics marked alone as a serious competitor while in the weight loss drug market in February soon after revealing promising data from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection As well as in March the comp